Choose ALUNBRIG® (brigatinib), Which Offers Efficacy in Previously Treated Patients
Brigatinib (ALUNBRIG) is an NCCN Category 2A recommended treatment option for patients post-crizotinib.1
ALTA STUDY DESIGN
The efficacy of ALUNBRIG was studied in a global, two-arm, open-label, multicenter study of adult patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who had progressed on crizotinib.2,3
Major efficacy outcome measure was confirmed overall response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) as evaluated by an Independent Review Committee (IRC).2
Additional efficacy outcome measures included investigator-assessed ORR, duration of response (DOR), intracranial ORR, and intracranial DOR.2
ALTA PATIENT DEMOGRAPHICS2,3
ALUNBRIG was studied in patients with locally advanced or metastatic ALK+ NSCLC.
ALUNBRIG demonstrated clinically meaningful overall response rates (ORR) following crizotinib2
Results from 8-month median follow-up2,a
In a 2-year median follow-upd—ALUNBRIG achieved meaningful PFS and OS after treatment with crizotinib3
Study Limitations: ALTA was not a controlled trial and was not prospectively designed for statistical comparisons between dosing arms.
In an 8-month median follow-up—ALUNBRIG had clinically meaningful intracranial responses post-crizotinib2
Results from 8-month median follow-up2,a
Duration of intracranial response was measured from date of first intracranial response until intracranial disease progression (new lesions, intracranial target lesion diameter growth ≥20% from nadir, or unequivocal progression of nontarget lesions) or death.
In a 2-year median follow-upd—ALUNBRIG achieved meaningful intracranial PFS post-crizotinib3
aThe median duration of follow-up was 8 months (range: 0.1-20.2).2
bThe recommended dosing regimen is 90 mg orally once daily for the first 7 days; then increase the dose to 180 mg orally once daily.2
c≥10 mm in longest diameter (at baseline).
dAdditional outcomes calculated as of September 29, 2017, 2 years after last enrollment (median follow-up of 19.6 months [range: 0.1-35.2] in the 90-mg arm and 24.3 months [range: 0.1-39.2] in the 90→180-mg arm).3
ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; NCCN, National Comprehensive Cancer Network® (NCCN®); ECOG, Eastern Cooperative Oncology Group; PR, partial response.